|
Sheila
Last June Genentech reached full enrollment with 3 week dosing, T-DM1, phase2 trial. This year they will choose whether to follow up on this effort with a phase3 evaluation.
If that decision is ‘go phase3’, then Genentech being Genentech, it shouldn’t take them long to see that trial get underway; clinicaltrials.gov registry will probably carry all particulars for participation.
|